Document Type : Research article
Authors
1 Department of Biochemistry. School of Biotechnology. Al Neelain University.
2 1. College of Veterinary Medicine, Sudan University of Science and Technology
Abstract
Keywords
Department of Biochemistry.
School of Biotechnology.
Al Neelain University.
Effect of combined Paracetamol and Glycyrrhiza glabra or Cinnamomumzeylanicum use in rats
(With four tables)
SaharA. Yousif *; O. F. Idris; H. I. Seri (1)
*Corresponding author: Sahar Ahmed Yousif. Sahar.ahmed88@yahoo.com
تأثير الاستخدام المشترک للباراسيتامول و عرق السوس أو القرفة في الجرذان
سحر أحمد يوسف، عمر فضل ادريس و هشام اسماعيل سري
أجريت هذه الدراسة لتسليط الضوء على بعض التأثيرات السميه لإستخدام الباراسيتامول مع أو بدون عرق السوس أوالقرفه في الجرذان. قسمت ذکور الجرذان لسبع مجموعات، احتوت کل مجموعه على سته جرذان بعمر اثنا عشر إسبوعاً. المجموعتان الأولى والثانيه أعطيتا الباراسيتامول بترکيز 500ملج/ل (في ماء الشرب) أو 500ملج/کجم (في الطعام) على التوالي. المجموعه التالثه أُطعمت عرق سوس بترکيز 6%، المجموعه الرابعه أُطعمت قرفه بترکيز 6% والمجموعتين الأخيرتين أُطعمتا خليط من الباراسيتامول بترکيز 500ملج/کجم مع عرق السوس بترکيز 6% أو القرفه بترکيز 6% لمدة إسبوعين وأربعة أسابيع. أما آخر مجموعه فأعطيت طعام وشراب من غير إضافات کمجموعة تحکم.
لُوحظ تأثير مرضي في الکبد والکلى في الجرذان التي أُطعمت باراسيتامول بترکيز 500ملج/ل أو 500ملج/کجم. أما الجرذان التي أُعطيت عرق سوس فقد سجلت بها أنيميا. إنخفاض مستوى الهيموغلوبين مصحوباً بزيادة ترکيز نشاط إنزيم AST وزيادة ترکيز اليوريا سُجلت في الجرزان التي أُعطيت القرفه. أنيميا وزيادة ترکيز نشاط إنزيمAST وزيادة ترکيز الألبيومين لُوحظت في الجرزان التي أُطعمت باراسيتامول مع عرق السوس. والجرذان التي أطعمت باراسيتامول مع القرفه فقد سُجل بها إرتفاع في ترکيز اليوريا.
Abstract
In this study we decided to throw light on some toxicological aspects of combined usage of Paracetamol with or without Glycyrrhiza glabra or Cinnamomum zeylanicum in rats. Seven groups each of six male Wistar rats (12 weeks-old) were used in this study. Paracetamol was provided to the first 2 groups at dose level of 500mg/L (in drinking water) or 500mg/kg (in feed), respectively. The third group received a diet containing 6% w/w G. glabra, a fourth group received a diet containing 6% w/w C. zeylanicum, and additional 2 groups received mixture of paracetamol at 500mg/kg and G. glabra or C. zeylanicum for 2 and 4 weeks. The last group remained without treatment as control group. Hepato-nephropathy was observed in the rats fed the diet containing paracetamol at 500mg/L and 500 mg/kg. Anaemia was recorded in rats supplemented with G. glabra. Decrease in haemoglobin level, increase in serum aspartate amino transferase (AST) activity and urea concentration were appearing in rats fed C. zeylanicum. Anaemia, increase activity of (AST) and increase in albumin level were observed in rats fed paracetamol and G. glabra. Increase in urea concentration in rats fed paracetamol and C. zeylanicum.
Key words: Paracetamol, G. glabra, C. zeylanicum, Toxicity, Hepatoprotective activity.
Introduction
Glycyrrhiza glabra, member of the family Leguminosea, locally known as "Liquorice" or Licorice is useful for many diseases as well as cough but it also helps to increase the appetite for facilitating proper evacuation of stools. It is mainly used as expectorant, anti- inflammatory, antipyretic and laxative for children and for treatment of gastric and duodenal ulcers and chronic fatigue syndrome (Foster, 1993; Leung and Foster, 1996).
Tyler (1994) and Blumenthal (1996) have shown that the active constituent, glycyrrhizin, stimulates the secretion of hormone by the adrenal cortex and that glycyrrhizin has similar chemical structure to corticosteroids released by the adrenals. The anti-bacterial activity of methanol extract of Glycyrrhiza glabra against Streptococcus mutants was described by Hwang et al., (2003).
Cinnamumum zeylanicum, a member of the family Lauraceae, is locally known as "Gerfa" and its bark is used in Sudan and other countries as carminative, antiseptic, stimulant, antiemetic, antidiarrhoeic and astringent in cosmetics often as skin lotion for the treatment of blotchy skin (Patrick et al., 2004). The therapeutic value of Cinnamon depends on the volatile oil, the most important ingredient is cinnnamic aldehyde, and the bark was found to contain some gum, a coloring matter and tannin (Chang et al., 2001).
Paracetamol (Acetaminophen, N-acetyl-P-aminophenol) is a potent analgesic and anti-pyretic agent but is relatively devoid of anti-inflammatory activity (Al-Swayeh et al., 2000). Unlike aspirin and related non-steroidal anti-inflammatory drugs (NSAID), it is the most widely used pharmaceutical analgesic and antipyretic agent in the world (Anker and Smilkstein, 1994; Farrell, 2002). Indeed, paracetamol pretreatment has actually been reported to protect against aspirin and ethanol-induced gastric mucosal damage in man (Stern et al, 1984). The high potency and lack of gastrointestinal side effects of this drug have led to the widespread use of paracetamol which is regarded as a safer alternative to NSAID for mild to moderate analgesia. However, high doses of paracetamol do cause severe and often fatal acute liver in man (Plevris et al., 1998).
Hepatic dysfunction due to ingestion or inhalation of hepatotoxins such as acetaminophen, cadmium chloride, ethanol, carbon tetrachloride (CCl4) and alkyl alcohols are increasing worldwide (Wolf, 1999). Paracetamol is a common antipyretic agent which can produce fatal hepatic necrosis by formation of metabolite N-acetyl -p-benzoquinoneimine in the liver (Wong, et al.; 1981; Savides and Oehme, 1983).
The main objective of this study is to evaluate the hepatoprotective effect of combined usage of paracetamol with Glycyrrhiza glabra or Cinnamomum zeylanicum in rats with emphasis on hepato-renal function.
Materials and methods
Wheat flour |
657g |
Dry meat |
220g |
Sodium chloride |
3g |
Oil |
120g |
Experimental design: the rats were allotted randomly into 7 groups, each of 6 rats. Rats in group 1 served as control and continued to be fed the normal diet and water. Groups 2 and 3 received drinking water containing paracetamol at 500mg/L or diet containing paracetamol at 500 mg/kg, respectively. Groups 4 and 5 received diet containing 6% (w/w) of Cinnamomum zeylanicum or 6% (w/w) of Glycyrrhiza glabra, respectively. Groups 6 and 7 received a diet that contained a mixture of paracetamol at 500mg/kg and 6% (w/w) of Cinnamomum zeylanicum or paracetamol at 500mg/kg and 6% (w/w) Glycyrrhiza glabra, respectively.
Blood Analyses: serum samples were analyzed for the activity of aspartate aminotransferase (AST), and alanine aminotransferase (ALT) according to Reitman and Frankel (1957); and alkaline phosphatase (ALP) (Tietz, 1995), and for concentration of total protein (King and Wooton, 1956), albumin (Bartholomew and Delany, 1966), globulin (globulins (g/l) were determined by deduction of the values of serum albumin from total serum protein values), bilirubin (Heinemann and Vogt, 1988), cholesterol (Allain et al., 1974); and urea (Fawcett and Scott, 1960).
Haemoglobin (Hb) concentration, red blood cells (RBC) count, packed cell volume (PCV), mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC) and white blood cells (WBC) count were determined using standard methods (Schalm et al., 1975).
Statistical Analysis: the significance of the differences between means was compared at each time point using Duncan’s multiple range test after ANOVA for one-way classified data (Snedecor and Cochran, 1989).
Results and discussion
In the Sudanese system of medicine, certain herbs are claimed to have medicinal properties against several disorders. The claimed therapeutic reputation has to be verified in a scientific manner. This study was conducted to investigate if "Gerfa" and "Liquorice" could provide some sort of hepato protection against Paracetamol hepatotoxicity.
Haematological changes: are summarized in tables (1 and 2). After 2 weeks of treatment as we could observe in table (1), the values of Hb (except in group7), MCV, MCH and MCHC were significantly lower (P<0.05) in all groups when compared with control group. The values of RBCs were significantly higher (P<0.05) in groups 2, 3, 4 and 5. The value of PCV was significantly lower (P<0.05) in group 2 than control and other groups. WBCs were significantly higher (p<0.05) in groups 2 and 4. Neutrophils were higher and lymphocytes were lower (p<0.05) in groups 2, 3, 5 and 7.
Based on above data, the lower level of MCV, MCH, and MCHC in groups 2 and 3 following 2 weeks of treatment, as we could observe in table (1) may be influenced by the higher value of Hb reported in control group. But results obtained by the end of the study ensure that the higher value of Hb following two weeks of feeding in the control group may be attributed to machinery fault, as the value of Hb in the different groups is in close relation with the control.
As shown in table (2), after 4 weeks of treatment, the values of Hb were higher (P<0.05) in groups 3 and 5. PCV and MCV were significantly higher (p<0.05) in all groups than control group. MCH and MCHC were lower (p<0.05) in all groups than control group. The values of RBCs were higher (p<0.05) in groups 2, 3, 5, 6 and 7. Neutrophils were lower and lymphocytes were higher (p<0.05) in groups 2, 5 and 7 than control and other groups.
The decrease in the level of MCV, MCH and MCHC in group 4 (6% G. glabra) and in group 6 (500 mg/kg paracetamol and 6% G. glabra), as we could observe in table (1) may indicate microcytic hypochromic anaemia. There was significant decrease in haemoglobin level with rats in group 5 (6% Cinnamomum zeylanicum) as shown in table (1), and this was also described by (Shah et al., 2004).
Serum biochemical changes: the obtained data are presented in table (3 and 4). Following 2 weeks of treatment, as we could observe in table (3), the activity of serum AST was significantly higher (p<0.05) in groups 2, 3, 4, 5, 6 and 7. The activity of serum ALT in groups 3, 4, and 7 was higher (p<0.05) than control group. Globulins concentration was lower (p<0.05) in groups 2-7 than control. Bilirubin was significantly lower (p<0.05) in groups 3, 5 and 7. Urea concentrations was lower (p<0.05) in group 6 than other groups as recorded in table (3).
After 4 weeks of treatment, as we could observe in table (4), the activity of serum AST was significantly (p<0.05) higher in groups 6 and 7 than control and other groups. The activity of serum ALT in groups 5 and 7 was significantly (p<0.05) higher than control group. The activity of ALP was significantly (p<0.05) lower in groups 5, 6 and 7. Albumin was significantly (p<0.05) higher in groups 4, 6 and 7 than control. Globulins level was significantly (p<0.05) lower in groups 3, 5, 6 and 7 than control and other groups. Bilirubin was significantly (p<0.05) lower in groups 2, 3 and 5 than control as recorded in table (4). Cholesterol was significantly (p<0.05) lower in group 6 than control and other groups. Urea concentration was significantly (p<0.05) higher in groups 2, 3, 5 and 7 than other groups.
Elevated activity of serum AST, ALT combined with decrease in globulin concentration as shown in table (3), following 2 weeks of treatment, may indicate an effect in the rat liver of groups 2 and 3. That may suggest paracetamol hepatotoxicity in rats. Sever hepatic necrosis was first observed in cats treated with paracetamol (25 mg/kg and then 50 mg/kg) for 22 weeks (Eder, 1964). In a similar study, Tuse and his colleagues (2009), observed hepatic damage produced by paracetamol (3 gm/kg; p.o.), which was reflected by increased levels of SGOT and SGPT as compared to control (p<0.001).
The liver was affected as evident by an increase in the activity of AST and ALT, decrease in activity of ALP and increase in albumin concentration, as shown in table (3), so 6% G. glabra does not exhibit hepatic-protection, a similar effect was recorded previously by (Ge Lin et al., 1999), and single dose (35mg/kg) did not show hepatic -protection, but high dose (200mg/kg) can do.
Also we observed neutrophils increase than control in this study, the macrophages and neutrophils are attracted to the damage areas and lead to additional protein thiol (Mitchell, 1988).
Rang and his colleagues (2007), reported that toxic doses (10-15 grams) of paracetamol cause potentially fatal hepatotoxicity. This occurs when the liver enzymes catalyzing the normal conjugation reactions are saturated, causing the drug to be metabolized instead by mixed function oxidases. The resulting toxic metabolite, N-acetyl-p-benzoquinoneimine, is inactivated by conjugation with glutathione, but when glutathione is depleted the toxic intermediate accumulates and reacts with nucleophilic constituents in the cell. This causes necrosis in the liver and also in the kidney tubules. The initial symptoms of acute paracetamol poisoning are nausea and vomiting, the hepatotoxicity being a delayed manifestation that occurs 24-48 hours later.
The data obtained in this study revealed significant increase in the activity of serum AST, ALT which was increased after 4 weeks and ALP was decreased. Also there was significant elevation in blood urea concentration after 4 weeks (from 36.3 to 67.0) as shown in table (4). A similar effect was recorded previously (Gawronska- Szklarz, et al., 2003) which may indicate an impairment of kidney function.
In group 7 (500 mg/kg paracetamol and 6% C. zeylanicum), there was increase in urea concentration after 4 weeks (table 4), which indicated a renal abnormality. Increase in albumin concentration, increased activity of serum AST and ALT and decrease activity of ALP as appearing in table (4), which may be related to liver lesion.
Katzung (2006), reported that paracetamol in therapeutic doses, a mild increase in hepatic enzymes may occasionally occur in the absence of jaundice; this is reversible when the drug is withdrawn. With larger doses, dizziness, excitement, and disorientation are seen. Ingestion of 15 g of acetaminophen may be fatal, death being caused by severe hepatotoxicity with centrilobular necrosis, sometimes associated with acute renal tubular necrosis. Early symptoms of hepatic damage include nausea, vomiting, diarrhea, and abdominal pain. Cases of renal damage without hepatic damage have occurred, even after usual doses of acetaminophen.
Conclusion
It is to be concluded that, Paracetamol was found to exhibit some degree of hepatotoxicity to rats at 500mg/L and 500mg/kg, excessive usage of paracetamol may lead to hepatotoxicity, nephrotoxicity. Consumption of G. glabra may cause fall in haemoglobin level. Usage of C. zeylanicum with paracetamol lead to an increase in the level of blood urea, and that may suggest impairment in kidney function.
References
Al- Swayeh, O. A.; Futter, L. E.; Clifford, R. H.; Del Soldato, P.; and Moore, P. K. (2000). Nitroparacetamol exhibits anti- inflammatory and anti-nociceptive activity. Br. J. Pharmacol. 130: 1453 – 1456.
Anker, A. L. and Smilkstein, M. J. (1994). Acetaminophen concepts and controversies. Emerg. Med. Clin. North. Am. 12 (2): 335 – 49.
Bartholomew, R. J.; Delany, A. M. (1966). Blood albumin determination. Proceedings of Australian Association of Clinical Biochemists. 1-214.
Blumenthal, M. (1996). Therapeutic Monograph on Medicinal products for Human Use. American Botanical Council, Austin, Texas.
Chang, S. T, Chen, P. F, and Chen, S. C, (2001). Anti - bacterial activity of leaf essential oils and their constituents from Cinnamoum osmophloem. Journal of Agriculture Food Chemistry 49, 183 – 188.
Eder, H. (1964). Chronic toxicity studies on phenacetin, N-acetyl-P-aminophenol (NAPA) and acetylsalicylic acid on cats. Acta. Pharmacol. Toxicol. 21: 197 – 204.
Farrell E. S. (2002). Acetaminophen Toxicity. Emergency Medicine, HarvardMedicalSchool; Program Director, Department of Emergency Medicine, Brigham and Women’s Hospital.
Fawcett, J. K.; Scott, J. E. (1960). A rapid and precise method for the determination of urea. J Clin Pathol. 13: 156-159.
Foster, S. (1993). Herbal Renaissance, Gibbs Smith Publisher. Layton, Utah.
Gawronska-Szklarz, B., Musial, D., Pawlik, A., Paprota, B. (2003). Effect of experimental diabetes on pharmacokinetic parameters of lidocaine and MEGX in rats. Pol. J. Pharmacol. 55:619-624.
Ge Lin; IvoP. Nnane; and Tin- Yan Cheng (1999). The effects of pretreatment with glycyrrhizin and glycyrrhetinic acid on the retrorsine-induced hepatotoxicity in rats. Toxicon, 37: 9, 1259 – 1270.
Heinemann G.;Vogt, W. (1988). The determination of bilirubin with a new enzymatic method (Dri-STAT bilirubin) using the Hitachi 704 selective analyzer. J. Clin. Chem. Clin. Biochem. 26(6):391-7.
Hwang, J., Shin, J.S. and Ehanje, T.Y. (2003). Anti-carcinogenic activity of some tropical medicinal plants against Streptococcus mutans. Skin Pharmacology and applied skin physiology 16: 84 – 90.
Katzung, B.G. (2006): Non steroidal anti-inflammatory drugs. In: Basic and clinical pharmacology. 10th edition. McGraw Hill Lange.
King, E.S.; Wooton, J.G.P. (1956). Microanalysis in: Medical Biochemistry. 3rd edition. Church hill, J. A. 57-60.
Leung, A.Y. and Foster, S. (1996). Encyclopedia of common Natural Ingredients used in foods, Drugs and cosmetics, 2nd edition, John Wily and Sons, New York.
Mitchell, J. R. (1988). Acetaminophen toxicity. N- Engl. J Med, 319: 1601 – 1602.
Patrick, M.E., Adcock, P.M., and Gomez, T.M., (2004). Salmonella enuritidin infections. United State Emergency Infections Diseases 10, 1 – 7.
Plevris, J.N.; Schina, M.; and Hayes, P.C. (1998). The management of acute liver failure. Aliment. Pharmacol. Ther. 12: 405 – 418.
Rang, H.P.; Dale, M.M.; Ritter, J.M.; Flower, R.J. (2007): Anti-inflammatory and immunosuppressant drugs. In: Rang and Dale's pharmacology. 10th edition. Churchill Livingstone. 227-237.
Reitman, S.; Frankel, S. (1957). A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Amer. J. Clin. Path. 28: 56 -63.
Savides, M.C. and Oehme, F.W. (1983). Acetaminophen and its toxicity. Journal ofApplied Toxicology, 3: 95–111.
Schalm, O.W., Jain, N.C. and Carroll, G.H. (1975). Veterinary Haematology, 3rd ed., Lea and Febiger, Philadelphia.
Shah, A.H.; Al- shareef, A.H.; Ageel A.M.; and Quershi, S. (2004).Toxicity studies in mice of common spices, Cinnamomum zeylanicum bark and Piper longum fruits. Plant Foods for Human Nutrition, 52: 231 – 239.
Snedecor, G. W., and Cochran, W. C. (1989). Statistical Methods, 8th ed. IowaStateUniversity Press, Ames, Iowa.
Stern, A.I.; Hogan, D.L.; Kahn, L.H.; Isenberg, J.I (1984). Protective effect of acetaminophen against aspirin- and ethanol- induces damage to human gastric mucosa. Gastroentterology. 86: 728 – 733.
Tietz, N.W. (1995). Clinical guide to laboratory tests. 3rd Edition. W. B. Saunders Co. Philadelphia, P.A.
Tuse, T. A.; Harle, U. N.; and Bore, V. V. (2009). Hepatoprotective activity of Colocasia antiquorum against experimentally induced liver injury in rats. Malaysian Journal Pharmaceutical Sciences. 7(2), 99–112.
Tyler, F. (1994). Herbs of choice: The Therapeutic Use of Phytomedicinals. Pharmaceutical products press, Binghamton, New York.
Wolf, P.L. (1999), Biochemical diagnosis of liver diseases, Indian Journal of ClinicalBiochemistry, 14: 59–90.
Wong, L.T.; Whitehouse, L.W.; Solemonraj, G. and Paul, C.J. (1981). Pathways of disposition of acetaminophen conjugate in the mouse, Toxicity Letter, 9: 145–151.
Table (1): Haematological changes in Wister rats fed normal diet (group 1), paracetamol 500 mg/L (group 2), paracetamol 500mg/kg (group 3), G. glabra 6% w/w (group 4), C. zeylanicum 6% w/w (group 5), paracetamol 500mg/kg and G. glabra 6%w/w (group 6), paracetamol 500mg/kg and C. zeylanicum 6%w/w(group 7) for2 weeks.
Parameters |
Treatment groups |
||||||
Group 1 |
Group 2 |
Group 3 |
Group 4 |
Group 5 |
Group 6 |
Group 7 |
|
Hb (g/dl) |
17.3±0.05 |
10.8±0.06* |
12.4±0.21* |
11.2±0.41* |
11.4±0.44* |
10.6±1.36* |
10.8±2.22 |
RBC (X106mm3) |
3.7±0.05 |
6.0±0.08* |
7.1±0.20* |
6.2±0.33* |
6.4±0.21* |
6.0±0.72 |
6.0±1.30 |
PCV (%) |
36.0±0.09 |
34.7±0.24* |
40.3±1.10 |
36.2±1.5 |
37.2±1.04 |
33.8±4.15 |
35.2±7.07 |
MCV (%) |
98.6±0.05 |
57.2±0.41* |
57.1±0.63* |
8.3±0.80* |
57.7±0.85* |
55.9±0.37* |
58.4±1.46* |
MCH(pg) |
47.4±0.05 |
17.9±0.31* |
17.6±0.24* |
18.1±0.29* |
17.7±0.38* |
17.6±0.25* |
17.9±0.24* |
MCHC (%) |
48.1±0.3 |
31.3±0.32* |
30.9±0.32* |
31.1±0.23* |
36.6±0.36* |
31.4±0.26* |
30.7±0.48* |
WBC(X103mm3) |
3.4±0.05 |
6.9±0.72* |
5.2±0.27 |
6.1±0.37* |
5.7±1.70 |
3.9±1.35 |
7.3±3.13 |
Neutrophils (%) |
10.0±0.57 |
50.2±8.70* |
53.7±3.20* |
46.4±10.11 |
51.8±2.05* |
49.9±10.69 |
47.6±2.18* |
Lymphocytes (%) |
90.0±0.57 |
49.8±8.70* |
46.3±3.2* |
53.6±10.11 |
48.2±2.05* |
50.1±10.69 |
52.4±1.81* |
Values are means ± SE.
* Means in the same row with asterisk are significantly different (p<0.05) with control group (group 1)
Table (2): Haematological changes in Wister rats fed normal diet (group 1), paracetamol 500 mg/L (group 2), paracetamol 500mg/kg (group 3), G. glabra 6% w/w (group 4), C. zeylanicum 6% w/w (group 5), paracetamol 500mg/kg and G. glabra 6%w/w (group 6), paracetamol 500mg/kg and C. zeylanicum 6%w/w(group 7) for 4weeks.
Parameters |
Treatment groups |
||||||
Group 1 |
Group 2 |
Group 3 |
Group 4 |
Group 5 |
Group 6 |
Group 7 |
|
Hb(g/dl) |
12.3±0.05 |
12.6±0.41 |
14.5±0.05* |
12.6±0.54 |
13.6±0.21* |
9.9±2.9 |
12.0±0.44 |
RBC (X106mm3) |
5.1±0.05 |
6.5±0.05* |
7.7±0.12* |
6.5±0.59 |
6.8±0..05* |
6.3±0.26* |
6.2±0.21* |
PCV (%) |
24.1±0.05 |
40.4±0.75* |
47.6±0.05* |
40.9±3.14* |
43.3±0.20* |
39.7±1.90* |
38.4±1.29* |
MCV (%) |
47.1±0.05 |
62.0±0.60* |
58.7±0.35* |
62.4±0.83* |
63.4±0.58* |
62.5±0.28* |
61.2±1.15* |
MCH (pg) |
24.1±0.05 |
19.3±0.64* |
18.1±0.37* |
19.4±0.82* |
20.0±0.08* |
15.4±4.25 |
19.2±0.26* |
MCHC (%) |
51.3±0.05 |
31.2±1.01* |
30.1±0.24* |
31.0±1.02* |
31.5±0.47* |
24.6±6.75* |
31.4±0.40* |
WBC (X103mm3) |
3.1±0.05 |
6.5±1.16 |
4.5±0.23 |
5.2±0.95 |
6.8±0.87* |
4.2±0.88 |
4.7±1.13 |
Neutrophilils (%) |
59.7±0.03 |
38.6±0.48* |
61.9±0.52* |
44.3±6.10 |
40.1±1.4* |
43.5±7.69 |
43.2±1.09* |
Lymphocytes (%) |
40.2±0.03 |
61.4±0.84* |
38.1±0.52* |
55.7±6.10 |
59.9±1.4* |
56.5±7.69 |
56.8±1.09* |
Values are means ± SE.
* Means in the same row with asterisk are significantly different (p<0.05) with control group (group 1)
Table (3): Serum biochemical tests in Wister rats fed normal diet (group 1), paracetamol 500 mg/L (group 2), paracetamol 500mg/kg (group 3), G. glabra 6% w/w (group 4), C. zeylanicum 6% w/w (group 5), paracetamol 500mg/kg and G. glabra 6%w/w (group 6), paracetamol 500mg/kg and C. zeylanicum 6%w/w (group 7) for 2 weeks.
Parameters |
Treatment groups |
||||||
Group 1 |
Group 2 |
Group 3 |
Group 4 |
Group 5 |
Group 6 |
Group 7 |
|
AST (i.u) |
41.00±0.57 |
152.6±5.45* |
193.0±14.29* |
181.0±31.0* |
181.0±23.15* |
195.6±16.82* |
166.3±14.62* |
ALT (i.u) |
15.0±0.57 |
25.3±3.17 |
49.3±5.04* |
40.5±2.50* |
56.6±21.05 |
26.6±4.05 |
36.6±3.18* |
ALP (i.u) |
318.0±0.57 |
256.3±23.20 |
273.6±17.23 |
229.0±23.0 |
245.0±49.89 |
236.0±46.70 |
208.0±39.15 |
Total protein g/dl) |
8.0±0.57 |
6.6±0.33 |
7.3±0.66 |
6.5±0.50 |
6.6±0.33 |
7.3±0.33 |
7.0±0.21 |
Albumin (g/dl) |
3.0±0.57 |
4.0±0.10 |
4.3±0.33* |
3.5±0.50 |
3.6±0.33 |
3.3±0.33 |
3.6±0.33 |
Globulins (g/dl) |
5.0±0.57 |
3.3±0.33* |
3.6±0.33* |
4.0±0.14* |
2.6±0.33* |
3.6±0.33* |
3.6±0.33* |
Bilirubin (mg/dl) |
0.7±0.05 |
0.5±0.05 |
0.43±0.03* |
0.50±0.18 |
0.46±0.033* |
0.50±0.05 |
0.46±0.06* |
Cholesterol (mg/dl) |
82.0±0.57 |
92.0±5.03 |
75.0±13.31 |
61.5±7.50 |
69.0±11.59 |
66.3±4.33 |
67.6±14.51 |
Urea (mg/dl) |
60.0±0.57 |
60.3±2.33 |
47.6±4.66 |
60.0±3.00 |
58.6±9.28 |
53.6±1.45* |
63.0±4.04 |
Values are means ± SE.
* Means in the same row with asterisk are significantly different (p<0.05) with control group (group 1)
Table (4): Serum biochemical tests in Wister rats fed normal diet (group 1), paracetamol 500 mg/L (group 2), paracetamol 500mg/kg (group 3), G. glabra 6% w/w (group 4), C. zeylanicum 6% w/w (group 5), paracetamol 500mg/kg and G. glabra 6%w/w (group 6), paracetamol 500mg/kg and C. zeylanicum 6%w/w (group 7) for 4weeks.
Parameters |
Treatment groups |
||||||
Group 1 |
Group 2 |
Group 3 |
Group 4 |
Group 5 |
Group 6 |
Group 7 |
|
AST(i.u) |
32.0±0.57 |
48.6±10.17 |
29.3±0.64 |
43.5±10.50 |
77.0±47.50 |
138.6±8.19* |
129.3±1.66* |
ALT(i.u) |
15.0±057 |
48.6±10.17 |
29.3±6.43 |
34.5±10.50 |
33.3±3.84* |
25.6±3.84 |
25.6±2.02* |
ALP(i.u) |
410±0.57 |
239.3±70.33 |
258.6±48.3 |
267.0±106.0 |
238.3±39.25* |
151.0±34.22* |
202.0±43.01* |
Total protein g/dl) |
8.0±0.57 |
7.3±0.33 |
7.0±0.57 |
7.0±0.12 |
6.6±0.33 |
6.6±0.33 |
7.0±0.21 |
Albumin(g/dl) |
2.6±0.33 |
3.6±0.33 |
3.6±0.33 |
4.0±0.15* |
2.0±1.00 |
3.6±0.33* |
4.0±0.41* |
Globulin(g/dl) |
4.6±0.33 |
4.0±0.32 |
3.3±0.33* |
3.5±0.50 |
3.0±0.13* |
3.0±.08* |
3.0±0.33* |
Bilirubin(mg/dl) |
0.66±0.03 |
0.53±0.53* |
0.53±0.33* |
0.55±0.05 |
0.53±0.03* |
0.46±0.88 |
0.46±0.66 |
Cholesterol(mg/dl) |
77.3±0.33 |
56.3±9.87 |
73.0±12.5 |
85.5±25.5 |
56.6±6.33 |
40.6±2.84* |
56.6±19.33 |
Urea(mg/dl) |
36.3±0.33 |
66.0±6.08* |
56.3±4.97* |
66±10.5 |
67.0±2.51* |
49.6±4.66 |
58.0±4.04* |
*Values are means ± SE.
* Means in the same row with asterisk are significantly different (p<0.05) with control group (group 1)